Bank of Montreal
LCTX icon

Bank of Montreal’s Lineage Cell Therapeutics LCTX Stock Holding History

Bank of Montreal’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-359,381
Closed -$913K – 3703
2021
Q3 		$913K Sell
359,381
-19,700
-5% -$50.5K ﹤0.01% 2551
2021
Q2 		$1.11M Buy
379,081
+102,093
+37% +$264K ﹤0.01% 2423
2021
Q1 		$701K Buy
276,988
+272,959
+6,775% +$655K ﹤0.01% 2441
2020
Q4 		$8K Hold
4,029
– – ﹤0.01% 4704
2020
Q3 		$4K Hold
4,029
– – ﹤0.01% 4507
2020
Q2 		$3K Hold
4,029
– – ﹤0.01% 4486
2020
Q1 		$3K Sell
4,029
-13,705
-77% -$13.6K ﹤0.01% 3781
2019
Q4 		$16K Buy
17,734
+4,175
+31% +$3.48K ﹤0.01% 4410
2019
Q3 		$13K Buy
13,559
+424
+3% +$439 ﹤0.01% 4319
2019
Q2 		$14K Buy
13,135
+7,664
+140% +$8.83K ﹤0.01% 4372
2019
Q1 		$7K Sell
5,471
-236
-4% -$294 ﹤0.01% 3959
2018
Q4 		$5K Sell
5,707
-86
-1% -$132 ﹤0.01% 4087
2018
Q3 		$11K Sell
5,793
-20
-0.3% -$42 ﹤0.01% 3902
2018
Q2 		$10K Buy
5,813
+727
+14% +$1.46K ﹤0.01% 3955
2018
Q1 		$12K Buy
5,086
+1,120
+28% +$2.63K ﹤0.01% 3704
2017
Q4 		$7K Buy
3,966
+137
+4% +$299 ﹤0.01% 3873
2017
Q3 		$10K Hold
3,829
– – ﹤0.01% 3698
2017
Q2 		$11K Buy
3,829
+1,029
+37% +$2.88K ﹤0.01% 3694
2017
Q1 		$8K Hold
2,800
– – ﹤0.01% 3611
2016
Q4 		$8K Hold
2,800
– – ﹤0.01% 3653
2016
Q3 		$10K Buy
2,800
+514
+22% +$1.42K ﹤0.01% 3552
2016
Q2 		$5K Sell
2,286
-2
-0.1% -$5 ﹤0.01% 3729
2016
Q1 		$6K Sell
2,288
-193
-8% -$431 ﹤0.01% 3742
2015
Q4 		$7K Hold
2,481
– – ﹤0.01% 3705
2015
Q3 		$6K Hold
2,481
– – ﹤0.01% 3603
2015
Q2 		$7K Buy
2,481
+1,168
+89% +$4.53K ﹤0.01% 3566
2015
Q1 		$5K Buy
1,313
+309
+31% +$1.07K ﹤0.01% 3629
2014
Q4 		$3K Sell
1,004
-1,548
-61% -$4.19K ﹤0.01% 3781
2014
Q3 		$6K Sell
2,552
-273
-10% -$657 ﹤0.01% 3758
2014
Q2 		$7K Buy
+2,825
New +$6.38K ﹤0.01% 4013

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of Montreal's LCTX Position: Q4 2021 in Review

Bank of Montreal sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 359,381 shares — an estimated $913K sold.

Bank of Montreal first reported a position in LCTX in Q2 2014 and held it in 30 quarters. The position peaked at $1.11M in Q2 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

  • Bank of Montreal reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bank of Montreal sold 359,381 Lineage Cell Therapeutics shares in Q4 2021, an estimated $913K.
  • Bank of Montreal first reported a position in Lineage Cell Therapeutics in Q2 2014 and held it in 30 quarters.
  • Bank of Montreal's Lineage Cell Therapeutics position peaked at $1.11M in Q2 2021.
  • 124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on Bank of Montreal's 13F filing for Q4 2021, filed 11 Feb 2022.